Mar 2021
![](https://s33007.pcdn.co/wp-content/uploads/2020/05/Gilead.jpg)
Agreement to Jointly Develop & Commercialize Long-acting, Investigational Combinations of Lenacapavir & Islatravir for the Treatment of HIV-1 with Merck
Financial Advisor
View Details >Jul 2020
$300 Million
![](https://s33007.pcdn.co/wp-content/uploads/2020/05/Gilead.jpg)
Jul 2020
![](https://s33007.pcdn.co/wp-content/uploads/2020/05/Gilead.jpg)
Sale of Spleen Tyrosine Kinase (SYK) Inhibitor Portfolio to Kronos Bio
Financial Advisor
View Details >May 2020
$2 Billion
![](https://s33007.pcdn.co/wp-content/uploads/2020/05/Gilead.jpg)